Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study
- PMID: 9165384
- DOI: 10.1016/s0165-0327(96)01427-9
Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study
Abstract
In a randomised multicentre study, the prophylactic efficacy of lithium and carbamazepine was compared in 144 patients with bipolar disorder (74 vs. 70 patients; observation period: 2.5 years; lithium serum level: 0.63 +/- 0.12 mmol/l, carbamazepine dose: 621 +/- 186 mg/day). Hospitalisations, recurrences, need of psychotropic comedication and adverse effects prompting discontinuation were defined as treatment failures. Survival analyses regarding hospitalisations and recurrences showed no statistically significant differences between both drugs. Results were distinctly in favour of lithium, considering recurrences combined with comedication (P = 0.041) and/or adverse effects (P = 0.007). Whereas adverse effects prompting discontinuation were more frequent under carbamazepine (9 vs. 4, ns), lithium patients reported more often slight/moderate side effects (61% vs. 21% after 2.5 years; P = 0.0006). In completers, recurrences occurred in 28% (lithium) vs. 47% (carbamazepine) of the patients (P = 0.06). Lithium seems to be superior to carbamazepine in maintenance treatment of bipolar disorder, in particular when applying broader outcome criteria including psychotropic comedication and severe side effects.
Similar articles
-
Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.Eur Arch Psychiatry Clin Neurosci. 1997;247(1):42-50. doi: 10.1007/BF02916252. Eur Arch Psychiatry Clin Neurosci. 1997. PMID: 9088805 Clinical Trial.
-
The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.Int Clin Psychopharmacol. 1999 Sep;14(5):277-81. Int Clin Psychopharmacol. 1999. PMID: 10529070 Clinical Trial.
-
Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified.Int Clin Psychopharmacol. 1999 Sep;14(5):283-5. Int Clin Psychopharmacol. 1999. PMID: 10529071 Clinical Trial.
-
Rational polypharmacy in the bipolar affective disorders.Epilepsy Res Suppl. 1996;11:153-80. Epilepsy Res Suppl. 1996. PMID: 9294735 Review.
-
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.J Clin Psychiatry. 2008;69 Suppl 5:9-15. J Clin Psychiatry. 2008. PMID: 19265635 Review.
Cited by
-
Bipolar disorder.BMJ Clin Evid. 2007 Aug 1;2007:1014. BMJ Clin Evid. 2007. PMID: 19454110 Free PMC article.
-
Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data.Int J Bipolar Disord. 2023 Oct 15;11(1):34. doi: 10.1186/s40345-023-00313-8. Int J Bipolar Disord. 2023. PMID: 37840048 Free PMC article.
-
History of Suicide Prevention with Lithium Treatment.Pharmaceuticals (Basel). 2025 Feb 14;18(2):258. doi: 10.3390/ph18020258. Pharmaceuticals (Basel). 2025. PMID: 40006071 Free PMC article. Review.
-
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.Eur Arch Psychiatry Clin Neurosci. 2012 Jun;262 Suppl 1:1-48. doi: 10.1007/s00406-012-0323-x. Eur Arch Psychiatry Clin Neurosci. 2012. PMID: 22622948
-
The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review.Int J Bipolar Disord. 2015 Dec;3(1):32. doi: 10.1186/s40345-015-0032-2. Epub 2015 Jul 18. Int J Bipolar Disord. 2015. PMID: 26183461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous